Clinical Trial: A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

This study has been completed.

Sponsored by: Hoffmann-La Roche
Information provided by: AIDS Clinical Trials Information Service

Purpose

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

Condition Treatment or Intervention Phase
HIV Infections
 Drug: Saquinavir
 Drug: Lamivudine
 Drug: Zidovudine
Phase II

MedlinePlus related topics:  AIDS

Study Type: Interventional
Study Design: Treatment, Safety Study

Further Study Details: 

Expected Total Enrollment:  30

A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Patients must have:

  • HIV antibody positive.
  • CD4 count >= 150 and <= 500 cells/mm3.

Exclusion Criteria

Prior Medication: Excluded:


Location Information


California
      Davies Med Ctr / c/o HIV Institute, San Francisco,  California,  94114,  United States

      Pacific Oaks Med Group / Rsch & Scientific Investigation, Sherman Oaks,  California,  91403,  United States

New York
      Columbia Presbyterian Med Ctr, New York,  New York,  10032,  United States

More Information

Study ID Numbers:  229N; NV15114
Record last reviewed:  July 1997
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002190
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources